

ASX: ALA

Arovella Therapeutics Limited
ACN 090 987 250



10 April 2025

Dear Shareholder

EXTRAORDINARY GENERAL MEETING (2025 EGM)

Notice is hereby given that the 2025 EGM of Arovella Therapeutics Limited (Arovella or the Company) will be held as a virtual meeting (Meeting or 2025 EGM) at 11.00am (AEST) on Thursday, 8 May 2025. The Meeting will be held via an online platform.

Arovella advises that no hard copy of the Notice of Extraordinary General Meeting and Explanatory Notes (Notice) will be circulated other than to shareholders who have expressly requested a hard copy. These documents can be accessed on the Company's website at <https://www.arovella.com/asx-announcements>

and via the ASX Market Announcements Platform under the Company's ASX Code (ALA).

If you have nominated an email address and elected to receive electronic communications from the Company, you will receive an email with a link to an electronic copy of the Notice of Meeting.

Your Vote is Important

The business of the 2025 EGM is important to all Shareholders and therefore it is important that Shareholders vote. Lodging a completed proxy is the simplest way to vote at the EGM.

The Company encourages shareholders to submit their votes in advance of the 2025 EGM as this will provide the Company with the best opportunity to prepare for the meeting. However, votes may also be submitted during the 2025 EGM. Proxy forms can be lodged online, by post or in person by following the proxy lodgement instructions on the proxy form. Proxy forms must be received by the Company's share registry, Automic, by 11am (Melbourne time) on Tuesday, 6 May 2025. Proxy forms received later than this time will be invalid.

If it becomes necessary or appropriate to make alternative arrangements for the holding or conducting of the 2025 EGM, the Company will make further information available through the ASX Market Announcements Platform and on its website.

Shareholder Communication Elections

Recent changes to the Corporations Act provide for shareholders electing and requesting to receive documents (including notices of meeting and the annual financial report) electronically or in hard copy. You can make a standing election and/or request to receive some or all of your communications from the Company in physical or electronic form.

Shareholders can also elect not to receive certain documents, including the annual financial report.

ASX: ALA

Arovella Therapeutics Limited
ACN 090 987 250



We encourage you to provide your email address so we can communicate with you electronically and you are provided with information regarding the Company more efficiently and sustainably.

If you have made a prior election or request to receive documents in a certain manner then that election will continue to apply until such time as you notify the Company that you change your election or request. Any shareholder who has not made a prior election and/or request to receive documents in a certain form will be treated by the Company as having elected to receive all documents in electronic form.

If you wish to update your communication preference, please refer to the insert titled "Update your details" or contact our share register, Automic below:

Telephone (within Australia): 1300 288 664

Telephone (outside Australia): +61 2 9698 5414

Email: hello@automicgroup.com.au

Website: <https://investor.automic.com.au/>

Yours faithfully

Tim Luscombe

Company Secretary

Arovella Therapeutics Ltd

investor@arovella.com

Arovella Therapeutics Limited

ACN 090 987 250

Notice of Extraordinary General Meeting

Date Thursday, 8 May 2025

Time 11:00am AEST

Location The Meeting will be held virtually via an online platform.

To participate you will need a desktop or mobile/tablet device with internet access. When you log onto the online platform to register to attend the Extraordinary General Meeting (EGM), you will need to provide your details (including SRN or HIN) to be verified as a Shareholder.

To register for the meeting, please click the link below:

https://us02web.zoom.us/webinar/register/WN_yAvV3da6RCuvE_oiH_Y4Jw

After registering, you will receive a confirmation email containing information about joining the Meeting.

You can view the meeting live, ask questions verbally or via a live text facility and cast votes at the appropriate times while the meeting is in progress.

Further information on how to participate in the Meeting is provided in the online meeting guide, which will be hosted on

https://web.automic.com.au/er/public/api/documents/BCT?fileName=Virtual_Meeting_Shareholder_Registration_Voting_Guide_.pdf

If Shareholders are unable to attend the Meeting, they are encouraged to return the Proxy Form to the Company in accordance with the instructions on the form. Returning the Proxy Form will not preclude a Shareholder from attending and voting at the Meeting, should they elect to do so.

IMPORTANT INFORMATION

General

This Notice of Meeting (including the Explanatory Memorandum) is dated 10 April 2025.

This document is important. The business to be considered at the Meeting is set out in the 'Business of Meeting' section below. The Explanatory Memorandum provides additional information on the Resolutions to which the business relates and forms part of the Notice of Meeting. This Notice of Meeting and Explanatory Memorandum is not investment advice. You should read this document in its entirety and seek your own financial and professional advice before making any decision on how to vote on the Resolutions.

A proxy form for the Meeting accompanies this Notice of Meeting. If you are in doubt as to what you should do, you should consult your legal, financial or other professional adviser.

Defined terms used in this Notice

Capitalised terms used in the Notice of Meeting are defined in the Glossary at the end of the Explanatory Memorandum, or where the relevant term is first used.

Any documents reproduced in this Notice of Meeting may have their own defined terms, which are sometimes different from those in the Glossary.

Questions from Shareholders

In order to provide an equal opportunity for all Shareholders to ask questions of the Board, we ask you to submit in writing any questions to the Company. Please send your questions via email to:

The Company Secretary
Tim Luscombe
investor@arovella.com

Written questions must be received by no later than **11:00am AEST on Friday, 2 May 2025**.

Your questions should relate to matters that are relevant to the business of the Extraordinary General Meeting, as outlined in this Notice of Meeting and Explanatory Memorandum.

The Chair of the Meeting will endeavour to address as many Shareholder questions and comments as possible during the course of the Meeting. However, there may not be sufficient time available at the meeting to address all of the questions and comments raised. Please note that individual responses may be sent to the enquiring party only, and may not be sent to all Shareholders.

Voting information

Entitlement to vote at the Meeting

The Board has determined, in accordance with section 1074E(2)(g)(i) of the Corporations Act and regulation 7.11.37 of the Corporations Regulations, that the Shareholders entitled to attend and vote (subject to any applicable voting exclusion) at the Meeting shall be those persons who are recorded on the register of members at **7.00pm AEST on Tuesday, 6 May 2025**. Accordingly, transfers registered after that time will be disregarded in determining entitlements to vote at the Meeting.

Voting on all items of business will be conducted on a poll.

Voting by proxy

- (a) A Shareholder entitled to attend and vote at the Meeting may appoint one proxy or, if the Shareholder is entitled to cast 2 or more votes at the Meeting, 2 proxies, to attend and vote instead of the Shareholder.
- (b) Where 2 proxies are appointed to attend and vote at the Meeting, each proxy may be appointed to represent a specified proportion or number of the Shareholder's voting rights at the Meeting.
- (c) A proxy need not be a Shareholder of the Company.
- (d) A proxy may be an individual or a body corporate. If a body corporate is appointed, the proxy form must indicate the full name of the body corporate and the full name or title of the individual representative of the body corporate for the Meeting.
- (e) A proxy form accompanies this Notice. If a Shareholder wishes to appoint more than 1 proxy, they may make a copy of the proxy form attached to this Notice. For the proxy form to be valid it must be received together with the power of attorney or other authority (if any) under which the form is signed, or a (notarially) certified copy of that power or authority by 11:00 am AEST on Tuesday, 6 May 2025, at the share registry, being Automic Registry Services as follows:

Online <https://investor.automic.com.au/#/loginsah> by following the instructions set out in the Proxy Form.

By post Automic
GPO Box 5193
Sydney NSW 2001

In person Automic
Level 5, 126 Phillip Street
Sydney NSW 2000

By email meetings@automicgroup.com.au

By facsimile +61 2 8583 3040

Proxy voting by the Chair

If you return your Proxy Form but do not nominate a proxy, the Chair will be your proxy and will vote on your behalf as you direct on the Proxy Form. If your nominated representative does not attend the Meeting then your proxy will revert to the Chair and the Chair will vote on your behalf as you direct on the Proxy Form.

If a proxy is not directed how to vote on an item of business or Resolutions, the proxy (including, if applicable, the Chair) may vote, or abstain from voting, as they think fit.

Except as prohibited by a voting exclusion applicable in respect of a Resolution, if you appoint the Chair as your proxy (or if the Chair is appointed by default) and you do not direct the Chair how to vote on the Resolutions, the Chair will vote your proxy in favour of each of the Resolutions, even if the Chair has an interest in the outcome of the Resolutions and votes cast by the Chair, other than as proxy holder, would



be disregarded because of that interest and even if the Resolution is connected directly or indirectly with remuneration of a member of the Key Management Personnel.

Documents available

You can view or download an electronic version of this Notice of Meeting at Arovella's website at <https://www.arovella.com/>.

Business of the Meeting Agenda

Resolution 1 – Ratification of issue of Placement Shares

To consider and, if thought fit, pass with or without amendment the following resolution as an **ordinary resolution**:

'That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 119,717,123 Shares on 5 March 2025 pursuant to the Placement on the terms and conditions set out in the Explanatory Memorandum accompanying this Notice.'

A voting exclusion statement applies to this Resolution. Please see the 'Voting Exclusion Statements' section below.

Resolution 2 – Ratification of issue of Placement Options

To consider and, if thought fit, pass with or without amendment the following resolution as an **ordinary resolution**:

'That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 39,905,625 Options on 5 March 2025 pursuant to the Placement on the terms and conditions set out in the Explanatory Memorandum accompanying this Notice.'

A voting exclusion statement applies to this Resolution. Please see the 'Voting Exclusion Statements' section below.

By order of the Board



Tim Luscombe
Company Secretary & CFO

Voting Exclusion Statements

Resolution 1 – Ratification of issue of Placement Shares	The Company will disregard any votes cast in favour of this resolution by or on behalf of a Placement Participant or an Associate of a Placement Participant.
Resolution 2 – Ratification of issue of Placement Options	The Company will disregard any votes cast in favour of this resolution by or on behalf of a Placement Participant or an Associate of a Placement Participant.

However, in each case above, this does not apply to a vote cast in favour of the Resolution by:

- (a) a person as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with directions given to the proxy or attorney to vote on the Resolution in that way; or
- (b) the Chair as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or
- (c) a Shareholder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
 - (i) the beneficiary provides written confirmation to the Shareholder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and
 - (ii) the Shareholder votes on the Resolution in accordance with directions given by the beneficiary to the Shareholder to vote in that way.

Explanatory memorandum

Arovella Therapeutics Limited ACN 090 987 250

This Explanatory Memorandum accompanies the Notice of Meeting in relation to the Extraordinary General Meeting of the Company to be held at **11:00 am AEST on Thursday, 8 May 2025**, virtually via an online platform.

The Explanatory Memorandum has been prepared to assist Shareholders in determining how to vote on the resolutions set out in the Notice of Meeting and is intended to be read in conjunction with the Notice of Meeting.

Resolution 1 – Ratification of issue of Placement Shares

Background

- 1 On 26 February 2025, the Company announced a capital raising comprised of a placement of Shares to institutional and sophisticated investors at an issue price of \$0.125 per Share, to raise approximately \$15 million (before costs).
- 2 The Company issued a total of 119,717,123 Shares to the Placement Participants under the Placement without Shareholder approval pursuant to the Company's capacity under Listing Rule 7.1, on 5 March 2025 (**Placement Shares**).
- 3 The Board intends to use the proceeds of the Placement to complete enrolment and report initial safety and efficacy data for the planned phase 1, first-in-human clinical trial for Arovella's lead product, ALA-101. The phase 1 clinical trial is for patients with CD19-positive non-Hodgkin's lymphoma and leukemia. Funds raised under the placement will also be used to strengthen Arovella's iNKT cell therapy pipeline and advance Arovella's solid tumour products, and for general working capital purposes.
- 4 Refer to the Company's ASX announcement dated 26 February 2025 and prospectus dated 26 February 2025 for further information on the Placement.
- 5 Resolution 1 seeks Shareholder ratification under Listing Rule 7.4 for the issue of the Placement Shares on 5 March 2025, so that the Placement Shares will be deemed to have been issued with Shareholder approval for the purposes of ASX Listing Rule 7.1, and will not deplete the Company's 15% Placement Capacity (as further detailed below).

Explanation

- 6 Subject to a number of exceptions, Listing Rule 7.1 limits the amount of Equity Securities that a listed company can issue without the approval of its shareholders over any 12-month period to 15% of the fully paid ordinary securities it had on issue at the start of that period (**15% Placement Capacity**).
- 7 All Placement Shares were issued on 5 March 2025 using the Company's available 15% Placement Capacity under Listing Rule 7.1.
- 8 Listing Rule 7.4 allows the shareholders of a listed company to ratify an issue of Equity Securities after it has been made or agreed to be made. If they do, the issue is taken to have been approved

under Listing Rule 7.1 and so does not reduce the listed company's 15% Placement Capacity to issue further Equity Securities without shareholder approval under that rule.

- 9 The Company wishes to retain as much flexibility as possible to issue additional Equity Securities in the future without needing to obtain Shareholder approval for such issues under Listing Rule 7.1. To this end, Resolution 1 seeks Shareholder ratification for the issue of Placement Shares on 5 March 2025, for the purposes of Listing Rule 7.4. If Shareholder approval is obtained, the Placement Shares will no longer be deducted from the Company's 15% Placement Capacity.

Specific information required under Listing Rule 7.5

- 10 In accordance with Listing Rule 7.5, the following information is provided in relation to the issue of Placement Shares the subject of this Resolution:

Resolution	Resolution 1
Recipients of issue	The Placement Shares were issued to professional and sophisticated investors known to the Company and/or introduced to the Company by Taylor Collison and Ord Minnett (the joint lead managers and bookrunners to the Placement).
Issue date and number and class of securities issued	119,717,123 fully paid ordinary shares were issued on 5 March 2025.
Consideration received for the issue	The Placement Shares were issued for \$0.125 per Share. The Company raised a total of approximately \$15 million (before costs) through the issue of Placement Shares on 5 March 2025.
Terms of securities	The Placement Shares will rank equally with all existing Shares on issue.
Purpose of issue and use of funds raised	Funds raised from the Placement will be used as detailed in paragraph 3 above.
Summary of agreement	The Placement Shares were issued pursuant to short form placement letters, pursuant to which Placement Participants agreed to be issued Placement Shares at an issue price of \$0.125 per Share. Under the terms of those letters, the Placement Participants were also offered one Placement Option for every three Placement Shares subscribed for under the Placement by them (the Company is seeking ratification of the issue of the Placement Options pursuant to Resolution 2).
Voting exclusion statement	A voting exclusion statement applies to Resolution 1, as set out in the Notice.

If Resolution 1 is approved/not approved

- 11 If Resolution 1 is passed, the Placement Shares issued on 5 March 2025 will be excluded when calculating the Company's 15% Placement Capacity, effectively increasing the number of Equity Securities that the Company can issue without Shareholder approval over the 12-month period following the issue date.
- 12 If Resolution 1 is not passed, the Placement Shares issued on 5 March 2025 will be included in calculating the Company's 15% Placement Capacity, effectively decreasing the number of Equity

Securities it can issue without Shareholder approval over the 12-month period following the issue date.

Directors' recommendation

- 13 The Directors unanimously recommend that Shareholders vote in favour of this Resolution 1 (subject to the applicable voting exclusions included in this Notice).

Chair's available proxies

- 14 The Chair of the Meeting intends to vote all available proxies in favour of Resolution 1.

Resolutions 2 – Ratification of issue of Placement Options

Background

- 15 On 26 February 2025, the Company announced a capital raising comprised of a placement of Shares to institutional and sophisticated investors at an issue price of \$0.125 per Share, to raise approximately \$15 million (before costs). Under the offer, for every three new Shares issued under the Placement, placement investors received one attaching option exercisable at \$0.15 and expiring on 24 May 2027.
- 16 The Company issued a total of 39,905,625 Options to the Placement Participants under the Placement without Shareholder approval pursuant to the Company's capacity under Listing Rule 7.1, on 5 March 2025 (**Placement Options**).
- 17 The Board intends to use the proceeds of the Placement to complete enrolment and report initial safety and efficacy data for the planned phase 1, first-in-human clinical trial for Arovella's lead product, ALA-101. The phase 1 clinical trial is for patients with CD19-positive non-Hodgkin's lymphoma and leukemia. Funds raised under the placement will also be used to strengthen Arovella's iNKT cell therapy pipeline and advance Arovella's solid tumour products, and for general working capital purposes.
- 18 Refer to the Company's ASX announcement dated 26 February 2025 and prospectus dated 26 February 2025 for further information on the Placement.
- 19 Resolution 2 seeks Shareholder ratification under Listing Rule 7.4 for the issue of the Placement Options on 5 March 2025, so that the Placement Options will be deemed to have been issued with Shareholder approval for the purposes of ASX Listing Rule 7.1, and will not deplete the Company's 15% Placement Capacity (as further detailed below).

Explanation

- 20 Subject to a number of exceptions, Listing Rule 7.1 limits the amount of Equity Securities that a listed company can issue without the approval of its shareholders over any 12-month period to 15% of the fully paid ordinary securities it had on issue at the start of that period (**15% Placement Capacity**).
- 21 All Placement Options were issued on 5 March 2025 using the Company's available 15% Placement Capacity under Listing Rule 7.1.
- 22 Listing Rule 7.4 allows the shareholders of a listed company to ratify an issue of Equity Securities after it has been made or agreed to be made. If they do, the issue is taken to have been approved under Listing Rule 7.1 and so does not reduce the listed company's 15% Placement Capacity to issue further Equity Securities without shareholder approval under that rule.

- 23 The Company wishes to retain as much flexibility as possible to issue additional Equity Securities in the future without needing to obtain Shareholder approval for such issues under Listing Rule 7.1. To this end, Resolution 2 seeks Shareholder ratification for the issue of Placement Options on 5 March 2025, for the purposes of Listing Rule 7.4. If Shareholder approval is obtained, the Placement Options will no longer be deducted from the Company's 15% Placement Capacity.

Specific information required under Listing Rule 7.5

- 24 In accordance with Listing Rule 7.5, the following information is provided in relation to the issue of Placement Shares the subject of this Resolution:

Resolution	Resolution 1
Recipients of issue	The Placement Options were issued to the Placement Participants, as the Placement Options were issued as free-attaching Options to the Placement Shares.
Issue date and number and class of securities issued	39,905,625 listed Options with an exercise price of \$0.15 and an expiry of 24 May 2027 were issued on 5 March 2025.
Consideration received for the issue	The Placement Options were issued for nil cash consideration as free-attaching Options, on the basis of one Placement Option for every three Placement Shares subscribed for under the Placement.
Terms of securities	Each Placement Option is exercisable into a fully paid ordinary share in the Company at an exercise price of \$0.15 and expire on 24 May 2027.
Purpose of issue and use of funds raised	<p>No funds were raised from the issue of the Placement Options as they were issued for nil cash consideration as free-attaching Options under the Placement. Funds raised from the Placement will be used as detailed in paragraph 17 above.</p> <p>If all 39,905,625 Placement Options are exercised prior to their expiry date of 24 May 2027, the Company will raise a total of \$5,985,843.75. The manner of application of any funds raised from the exercise of Placement Options will depend on when Placement Options are exercised and the status of the Company's activities and requirements at the relevant time. As at the date of this Explanatory Memorandum, the Company expects that it would apply any such funds raised from the exercise of the Placement Options towards strengthening the Company's iNKT cell therapy pipeline and advancing its solid tumor products, and its general working capital requirements.</p>
Summary of agreement	The Placement Options were offered to Placement Participants pursuant to the short form placement letters described in the information provided for the purposes of Listing Rule 7.5 in connection with Resolution 1 under paragraph 10 above.
Voting exclusion statement	A voting exclusion statement applies to Resolution 1, as set out in the Notice.

If Resolution 2 is approved/not approved

- 25 If Resolution 2 is passed, the Placement Options issued on 5 March 2025 will be excluded when calculating the Company's 15% Placement Capacity, effectively increasing the number of Equity Securities that the Company can issue without Shareholder approval over the 12-month period following the issue date.
- 26 If Resolution 2 is not passed, the Placement Options issued on 5 March 2025 will be included in calculating the Company's 15% Placement Capacity, effectively decreasing the number of Equity Securities it can issue without Shareholder approval over the 12-month period following the issue date.

Directors' recommendation

- 27 The Directors unanimously recommend that Shareholders vote in favour of this Resolution 2 (subject to the applicable voting exclusions included in this Notice).

Chair's available proxies

- 28 The Chair of the Meeting intends to vote all available proxies in favour of Resolution 2.

Glossary

Arovella Therapeutics Limited ACN 090 987 250

15% Placement Capacity	has the meaning given to that term in paragraph 6 of the Explanatory Memorandum.
AEST	means Australian Eastern Standard Time.
Associate	has the meaning given to that term in the Listing Rules.
ASX	means ASX Limited ACN 008 624 691 or the securities exchange operated by it (as the case requires).
Board	means the board of directors of the Company.
Business Day	has the meaning given to that term in the Listing Rules.
Chair	means the Chair of the Meeting.
Company or Arovella	means Arovella Therapeutics Limited (ACN 090 987 250).
Constitution	means the constitution of the Company, as amended or varied from time to time.
Corporations Act	means the <i>Corporations Act 2001</i> (Cth).
Corporations Regulations	means the <i>Corporations Regulations 2001</i> (Cth).
Directors	means the directors of the Company.
Equity Security	has the meaning given in the Listing Rules.
Explanatory Memorandum	means the explanatory memorandum enclosed with the Notice of Meeting.
Key Management Personnel or KMP	means those persons having authority and responsibility for planning, directing, and controlling the activities of the Company, directly or indirectly, including any Director (whether executive or otherwise) of the Company.
Listing Rules	means the listing rules of ASX.
Meeting	means the Company's extraordinary general meeting the subject of this Notice of Meeting.
Notice or Notice of Meeting	means this notice of meeting and includes the Explanatory Memorandum.
Option	means an option to acquire a Share.
Ord Minnett	means Ord Minnett Limited (ACN 002 733 048)
Placement	means the Company's capital raising placement of Shares, together with attaching Options on the basis of 1 attaching Option for every 3 Shares subscribed for under the placement, to institutional and sophisticated investors to raise approximately \$15 million (before costs), as announced by the Company to the ASX on 26 February 2025.
Placement Options	means the listed 39,905,625 Options issued to the Placement Participants, each exercisable into a Share at \$0.15 on or before 24 May 2027.

Placement Participants	means the institutional and sophisticated investors who participated in the Placement and were issued Placement Shares and Placement Options.
Placement Shares	means the 119,717,123 Shares issued to the institutional and sophisticated investors under the Placement, with an issue price of \$0.125 per Share.
Resolutions	means the resolutions that are set out and explained in the Notice of Meeting.
Share	means a fully paid ordinary share in the capital of the Company.
Shareholder	means a person who is the registered holder of one or more Shares.
Taylor Collison	means Taylor Collison Limited (ACN 008 172 450)

Proxy Voting Form

If you are attending the virtual Meeting please retain this Proxy Voting Form for online Securityholder registration.

Your proxy voting instruction must be received by **11.00am (AEST) on Tuesday, 06 May 2025**, being **not later than 48 hours** before the commencement of the Meeting. Any Proxy Voting instructions received after that time will not be valid for the scheduled Meeting.

SUBMIT YOUR PROXY

Complete the form overleaf in accordance with the instructions set out below.

YOUR NAME AND ADDRESS

The name and address shown above is as it appears on the Company's share register. If this information is incorrect, and you have an Issuer Sponsored holding, you can update your address through the investor portal: <https://investor.automic.com.au/#/home> Shareholders sponsored by a broker should advise their broker of any changes.

STEP 1 – APPOINT A PROXY

If you wish to appoint someone other than the Chair of the Meeting as your proxy, please write the name of that Individual or body corporate. A proxy need not be a Shareholder of the Company. Otherwise if you leave this box blank, the Chair of the Meeting will be appointed as your proxy by default.

DEFAULT TO THE CHAIR OF THE MEETING

Any directed proxies that are not voted on a poll at the Meeting will default to the Chair of the Meeting, who is required to vote these proxies as directed. Any undirected proxies that default to the Chair of the Meeting will be voted according to the instructions set out in this Proxy Voting Form, including where the Resolutions are connected directly or indirectly with the remuneration of Key Management Personnel.

STEP 2 - VOTES ON ITEMS OF BUSINESS

You may direct your proxy how to vote by marking one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as he or she chooses. If you mark more than one box on an item your vote on that item will be invalid.

APPOINTMENT OF SECOND PROXY

You may appoint up to two proxies. If you appoint two proxies, you should complete two separate Proxy Voting Forms and specify the percentage or number each proxy may exercise. If you do not specify a percentage or number, each proxy may exercise half the votes. You must return both Proxy Voting Forms together. If you require an additional Proxy Voting Form, contact Automic Registry Services.

SIGNING INSTRUCTIONS

Individual: Where the holding is in one name, the Shareholder must sign.

Joint holding: Where the holding is in more than one name, all Shareholders should sign.

Power of attorney: If you have not already lodged the power of attorney with the registry, please attach a certified photocopy of the power of attorney to this Proxy Voting Form when you return it.

Companies: To be signed in accordance with your Constitution. Please sign in the appropriate box which indicates the office held by you.

Email Address: Please provide your email address in the space provided.

By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible) such as a Notice of Meeting, Proxy Voting Form and Annual Report via email.

CORPORATE REPRESENTATIVES

If a representative of the corporation is to attend the Meeting the appropriate 'Appointment of Corporate Representative' should be produced prior to admission. A form may be obtained from the Company's share registry online at <https://automicgroup.com.au>.

Lodging your Proxy Voting Form:

Online

Use your computer or smartphone to appoint a proxy at <https://investor.automic.com.au/#/loginsah> or scan the QR code below using your smartphone

Login & Click on 'Meetings'. Use the Holder Number as shown at the top of this Proxy Voting Form.



BY MAIL:

Automic
GPO Box 5193
Sydney NSW 2001

IN PERSON:

Automic
Level 5, 126 Phillip Street
Sydney NSW 2000

BY EMAIL:

meetings@automicgroup.com.au

BY FACSIMILE:

+61 2 8583 3040

All enquiries to Automic:

WEBSITE:

<https://automicgroup.com.au>

PHONE:

1300 288 664 (Within Australia)
+61 2 9698 5414 (Overseas)

